Abstract |
Background: Few data are available regarding the effectiveness of immune checkpoint inhibitors in advanced upper tract urothelial carcinoma (UTUC) patients. Methods: To provide a real-world experience with anti-PD-1/PD-L1-based therapy in UTUC patients, we involved an Italian network in a multicenter retrospective analysis. Results: A total of 78 UTUC patients were enrolled. The median follow-up was 25.1 months. The median progression-free survival (mPFS) was 2.2 months (95% CI 1.8-2.6), and the median OS (mOS) was 6.0 months (95% CI 3.6-8.4). The Sonpavde score (including performance status > 0, hemoglobin < 10 g/dl, liver metastases, time from prior chemotherapy ≥ 3 months) split the patients into three groups (0 vs 1 vs 2-4 factors), efficiently predicting the OS and PFS outcome at the multivariate analyses (p < 0.0001). Conclusion: The prognosis of unselected UTUC patients is still unsatisfactory. The Sonpavde score was validated for the first time in an UTUC population, as a useful tool for the treatment decision-making process.
|
Authors | Melissa Bersanelli, Giulia Mazzaschi, Patrizia Giannatempo, Daniele Raggi, Elena Farè, Marco Maruzzo, Umberto Basso, Ugo De Giorgi, Francesca Vignani, Giuseppe Luigi Banna, Marco Stellato, Rosa Tambaro, Emanuele Naglieri, Tania Losanno, Giuseppe Procopio, Sandro Pignata, Andrea Necchi, Sebastiano Buti |
Journal | Immunotherapy
(Immunotherapy)
Vol. 14
Issue 2
Pg. 107-114
(02 2022)
ISSN: 1750-7448 [Electronic] England |
PMID | 34784782
(Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, Validation Study)
|
Chemical References |
- Immune Checkpoint Inhibitors
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Female
- Follow-Up Studies
- Humans
- Immune Checkpoint Inhibitors
(immunology, therapeutic use)
- Immunotherapy
(methods)
- Italy
- Male
- Medical Oncology
(methods)
- Middle Aged
- Reproducibility of Results
- Retrospective Studies
- Societies, Medical
- Survival Analysis
- Treatment Outcome
- Urologic Neoplasms
(drug therapy, immunology, pathology)
- Urothelium
(drug effects, immunology, pathology)
|